Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Frontiers in Cell and Developmental BiologyOpen Access

Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

GZGaia ZuccolottoIstituto Oncologico VenetoARAntonio RosatoUniversity of PaduaLMLorenzo MortaraUniversity of Insubria

Discussion

Loading...

Member takes

Overview

Immunotherapy demonstrates improved outcomes in bladder cancer, highlighting innovative strategies like viral vectors and antibody-drug conjugates.

Key Points

  • Immunotherapy showcases advancements that improve outcomes in bladder cancer treatment, enhancing patient management.
  • Immune checkpoint inhibitors play a crucial role in addressing BCG-unresponsive disease, indicating major therapeutic potential.
  • Innovative approaches like viral vectors and nanotechnology enhance precision targeting of tumor antigens, improving efficacy.
  • The shift towards personalized interventions supports better management strategies in bladder cancer treatment, emphasizing tailored approaches.

Cite This Study

Zuccolotto et al. (2025) studied this question.

synapsesocial.com/papers/693624a44fa91c937236c23bhttps://doi.org/10.3389/fcell.2025.1719978
View Full Paper
Ask AI
Bookmark
Share